Annual Meeting GU 2017: Most Interesting Research on Prostate Cancer

Annual Meeting GU 2017: Most Interesting Research on Prostate Cancer

obr

2 years
603 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses the research he found most intriguing at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
Up Next Autoplay
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
1 Views
Cancer-News 4 hours
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 4 hours
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
1 Views
Cancer-News 4 hours
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 3 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 3 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 3 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
2 Views
Cancer-News 3 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 5 days